lunes, 14 de mayo de 2007

Bibliografia sobre HME/OMC: Español e Inglés

1. Beitins IZ. Opportunities and challenges in pediatric clinical research. J Clin Endocrinol Metab 1999; 84: 4302-4306.
2. Argente J, Pérez-Jurado LA, Sotos JF. Bases moleculares de la patología del crecimiento. Rev Esp Ped 2000 (en prensa).
3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa,K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
4. Le Roith D, Butler AA. Insulin-like growth factors in pediatric health and disease. J Clin Endocrinol Metab 1999; 84: 4355-4361.

5. Parks JS, Brown MR, Hurley DL, Phelps CJ, Wajnrajch MP. Heritable disorders of pituitary development. J Clin Endocrinol Metab 1999; 84: 4362-4370.
6. López-Bermejo A, Buckway CK, Rosenfeld RG. Genetic defects of the growth hormone-insulin-like growth factor axis. TEM 2000; 11: 39-49.
7. Rao E, Weiss B, Takami M, y cols. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nauture Genet 1997; 16: 54-62.

8. Binder G, Schwarze CP, Ranke MB. Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone. J Clin Endocrinol Metab 2000; 85: 245-249.
9. Conley ME, Burks AW, Herrog HG, Puck JM. Molecular analysis of X-linked agammaglobulinemia with growth hormone deficiency. J Pediatr 1992; 119: 392-397.
10. Ogata T, Tomita K, Hida A, Matsuo N, Nakahori Y, Nakagome Y. Chromosomal localization of a Y specific growth gene(s). J Med Genet 1995; 32 (7): 572-575.
11. Joyce CA, Sharp A, Walker JM, Bullman H, Temple IK. Duplication of 7p12.1-p13, including GRB10 and IGFBP1, in a mother and daughter with features of Silver-Russell syndrome. Hum Genet 1999; 105: 273-280.

12. Monk D, Wakeling EL, Proud V, Hitchins M, Abu-Amero SN, Stanier P, Preece MA, Moore GE. Duplication of 7p11.2-p13, including GRB10, in Silver-Russell syndrome. Am J Hum Genet 2000; 66: 36-46.
13. Sotos JF. Overgrowth, section II. Clin Pediatr 1996; 35: 579-590. 14. Eugster EA, Pescovitz OH. Gigantism. J Clin Endocrinol Metab 1999; 84: 4379-4384.
15. Juul A. Skakkebaek NE. Prediction of the outcome of growth hormone provocative testing in short children by measurement of serum levels of IGF-I and IGFBP-3. J Pediatr 1997; 130: 197-204.
16. Nagel BHP, Palmbach M, Ranke MB. Magnetic resonance imaging in growth hormone deficiency. En: Ranke Mb, Wilton P, eds.. Growth hormone therapy in KIGS-10 years’experience. Heidelberg, Leippzig: Barth; 1999; 65-71.

17. Guyda HJ. Four decades of growth hormone therapy for short children: Whay have we achieved? J Clin Endocrinol Metab 1999; 84: 4307-4316.
18. Laron Z. The essential role of IGF-I lessons from the long-term study and treatment of children and adults with Laron syndrome. J Clin Endocrinol Metab 1999; 84: 4397-4404.
19. Laron Z. Clinical use of insulin-like growth factor-I. Yes or no? Pediatr Drugs 1999; 1: 155-159.
20. Caplan AL, Wilson JM. The ethical challenges of in utero gene therapy. Nat Genet 2000; 24: 107.

No hay comentarios: